Advancement of Engineered Bacteria for Orally Delivered Therapeutics
Small · 2023-11 · 19 (48)
DOI: 10.1002/smll.202302702 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 03.08.2023. Verfasst von Peilin Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China. Hauptthemen laut MEDLINE: Drug Delivery Systems, Bacteria. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 172 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
The use of bacteria and their biotic components as therapeutics has shown great potential in the treatment of diseases. Orally delivered bacteria improve patient compliance compared with injection‐administered bacteria and are considered the preferred mode. However, due to the harsh gastrointestinal environment, the viability and therapeutic efficacy of orally delivered bacteria are significantly reduced in vivo. In recent years, with the rapid development of synthetic biology and nanotechnology, bacteria and biotic components have been engineered to achieve directed genetic reprogramming for construction and precise spatiotemporal control in the gastrointestinal tract, which can improve viability and therapeutic efficiency. Herein, a state‐of‐the‐art review on the current progress of engineered bacterial systems for oral delivery is provided. The different types of bacterial and biotic components for oral administration are first summarized. The engineering strategies of these bacteria and biotic components and their treatment of diseases are next systematically summarized. Finally, the current challenges and prospects of these bacterial therapeutics are highlighted that will contribute to the development of next‐generation orally delivered bacteriotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
ORCID-Profile: Peilin Guo, Xin Li, Wei Wei
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Guo, P., Wang, S., Yue, H., Zhang, X., Ma, G., Li, X., & Wei, W. (2023). Advancement of Engineered Bacteria for Orally Delivered Therapeutics. Small, 19(48). https://doi.org/10.1002/smll.202302702
Vancouver
Guo P, Wang S, Yue H, Zhang X, Ma G, Li X, et al. Advancement of Engineered Bacteria for Orally Delivered Therapeutics. Small. 2023;19(48). doi:10.1002/smll.202302702
BibTeX
@article{Guo2023,
author = {Guo, Peilin and Wang, Shuang and Yue, Hua and Zhang, Xiao and Ma, Guanghui and Li, Xin and Wei, Wei},
title = {Advancement of Engineered Bacteria for Orally Delivered Therapeutics},
journal = {Small},
year = {2023},
volume = {19},
number = {48},
doi = {10.1002/smll.202302702}
}
EUVIMED